BioHarvest Sciences (BHST) Projected to Post Quarterly Earnings on Monday

Key Points

• BioHarvest Sciences (NASDAQ:BHST) is set to announce its Q2 2025 earnings on August 11, with analysts predicting a loss of ($0.11) per share and revenue of $8.53 million.
• In its previous earnings report on May 15, the company reported ($0.13) EPS which exceeded expectations, but revenue fell short at $7.64 million.
• Despite past performance, analysts maintain a positive outlook with a "buy" rating and price targets of $14.00 and $15.00 from HC Wainwright and Craig Hallum respectively.

BioHarvest Sciences (NASDAQ:BHST - Get Free Report) is expected to be announcing its Q2 2025 earnings results before the market opens on Monday, August 11th. Analysts expect BioHarvest Sciences to post earnings of ($0.11) per share and revenue of $8.53 million for the quarter.

BioHarvest Sciences (NASDAQ:BHST - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.02. The firm had revenue of $7.64 million for the quarter, compared to analysts' expectations of $8.93 million. BioHarvest Sciences had a negative net margin of 31.30% and a negative return on equity of 307.04%. On average, analysts expect BioHarvest Sciences to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

BioHarvest Sciences Stock Performance

Shares of BHST traded down $0.17 during mid-day trading on Tuesday, reaching $7.50. 1,367 shares of the company's stock traded hands, compared to its average volume of 14,608. The business's 50-day moving average price is $7.03 and its 200-day moving average price is $6.27. The stock has a market capitalization of $123.19 million, a P/E ratio of -15.00 and a beta of 0.67. BioHarvest Sciences has a 12 month low of $4.66 and a 12 month high of $7.99.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. HC Wainwright reiterated a "buy" rating and set a $14.00 price objective on shares of BioHarvest Sciences in a research note on Tuesday, April 8th. Craig Hallum started coverage on shares of BioHarvest Sciences in a research report on Monday, May 5th. They issued a "buy" rating and a $15.00 price target on the stock.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.